Latest Therapeutics News

Page 1 of 90
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
Ada Torres
Ada Torres
18 Nov 2026
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
Ada Torres
13 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
Anteris Technologies reported a wider third-quarter loss as spending accelerated on its PARADIGM heart-valve trial and manufacturing expansion. The company ended September with US$236.3 million in cash, but also retained unresolved weaknesses in financial reporting controls.
Ada Torres
Ada Torres
11 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
Neurizon says it has removed its remaining Obsidian convertible notes while targeting $6.3 million in new equity ahead of the pivotal NUZ-001 ALS readout. The funding plan reduces immediate conversion uncertainty, but the proposed Share Purchase Plan and possible future facility drawdown leave execution questions open.
Ada Torres
Ada Torres
5 Nov 2026
Cynata Therapeutics has completed its $912,962 entitlement offer and secured firm commitments for a further $550,000 placement. The second raise still requires shareholder approval and will bring additional shares and options into an already heavily funded capital structure.
Ada Torres
Ada Torres
4 Nov 2026

Browse the archive

Full archive